Lisata Therapeutics
LSTA
33 hedge funds and large institutions have $3.32M invested in Lisata Therapeutics in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 3 closing their positions.
106% more call options, than puts
Call options by funds: $272K | Put options by funds: $132K
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
3% more funds holding
Funds holding: 32 → 33 (+1)
0.14% more ownership
Funds ownership: 0.66% → 0.8% (+0.14%)
1% less capital invested
Capital invested by funds: $3.37M → $3.32M (-$47.1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$381K |
| 2 |
Renaissance Technologies
New York
|
+$188K |
| 3 |
Two Sigma Advisers
New York
|
+$107K |
| 4 |
VF
Virtu Financial
New York
|
+$83.2K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$80K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$152K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$66K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$19.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$13.1K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5.53K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KFS
26
Kelly Financial Services
Braintree,
Massachusetts
| $14 | – | – | – |
|
|
RE
27
RBC Europe
London,
United Kingdom
| $14 | – | – | – |
|
|
SM
28
Sabby Management
Miami Beach,
Florida
| – | -$152K | -6,400 | Closed |
|
29
Millennium Management
New York
| – | -$44 | -1,644 | Closed |
|
|
TWA
30
TCI Wealth Advisors
Tucson,
Arizona
| – | -$1K | -20 | Closed |
|
LSTA Hedge Fund Activity: Q4 2020 in Review
33 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2020, worth a combined $3.32M — down 1.4% from $3.37M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LSTA positions and 3 closed out — a net gain of 2 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $381K. The largest seller was Sabby Management, exiting entirely with an estimated $152K sold.
- 33 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2020, up from 32 in Q3 2020.
- Funds reported $3.32M of Lisata Therapeutics stock for Q4 2020, down 1.4% quarter-over-quarter.
- 5 funds opened new Lisata Therapeutics positions in Q4 2020 and 3 closed out, a net change of +2 holders.
- The largest Lisata Therapeutics buyer in Q4 2020 was Anson Funds Management, an estimated $381K added.
- The largest Lisata Therapeutics seller in Q4 2020 was Sabby Management, an estimated $152K sold.
Based on aggregated 13F filings for Q4 2020.